Scarica l'app Stockscreener
2.98
1.17%
-0.00
Precedente Chiudi:
$2.98
Aprire:
$2.98
Volume 24 ore:
10,971
Relative Volume:
0.03
Capitalizzazione di mercato:
$146.28M
Reddito:
$230.47M
Utile/perdita netta:
$30.28M
Rapporto P/E:
4.8852
EPS:
0.61
Flusso di cassa netto:
$38.86M
1 W Prestazione:
-2.16%
1M Prestazione:
-6.21%
6M Prestazione:
+5.56%
1 anno Prestazione:
-41.33%
Intervallo 1D:
$2.941
$2.99
Intervallo di 1 settimana:
$2.925
$3.1304
Portata 52W:
$2.225
$5.26
Puma Biotechnology Inc Stock (PBYI) Company Profile
Nome
Puma Biotechnology Inc
Settore
Industria
Telefono
(424) 248-6500
Indirizzo
10880 WILSHIRE BLVD., LOS ANGELES, CA
Confronta PBYI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
2.99 | 146.28M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
497.69 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.36 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.90 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.27 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
246.77 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Underperform |
| 2019-10-08 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-10 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2019-01-17 | Iniziato | Leerink Partners | Mkt Perform |
| 2019-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-11-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-11-02 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Iniziato | Goldman | Sell |
| 2018-05-11 | Reiterato | Stifel | Buy |
| 2017-11-10 | Reiterato | Citigroup | Buy |
| 2017-11-10 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Reiterato | Stifel | Buy |
| 2017-09-11 | Reiterato | Credit Suisse | Outperform |
| 2017-07-10 | Ripresa | Leerink Partners | Outperform |
| 2017-06-06 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Reiterato | RBC Capital Mkts | Sector Perform |
Mostra tutto
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results - BioSpace
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why - MSN
Is The Options Market Predicting A Spike In Puma Biotechnology Stock? - Barchart.com
Is the Options Market Predicting a Spike in Puma Biotechnology Stock? - Yahoo Finance
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential - Seeking Alpha
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Puma Biotech Expands Team: New Hires Receive Strategic Stock Compensation Package - Stock Titan
Further weakness as Puma Biotechnology (NASDAQ:PBYI) drops 11% this week, taking five-year losses to 55% - simplywall.st
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 - BioSpace
Groundbreaking Clinical Trial: Neratinib's Novel Combination Approach Targets HER2 Tumors - Stock Titan
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Why Investors Are Buzzing About Puma Biotechnology’s Earnings: Unpacking the Details - procarsrl.com.ar
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now - MSN
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Checking in on Puma Biotechnology Inc (PBYI) after recent insiders movement - Knox Daily
Rhumbline Advisers Lowers Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26% - Simply Wall St
Puma Biotechnology (NASDAQ:PBYI) Rating Lowered to Buy at StockNews.com - Armenian Reporter
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by StockNews.com - Defense World
We Think Puma Biotechnology's (NASDAQ:PBYI) Healthy Earnings Might Be Conservative - Yahoo Finance
Puma Biotech grants stock award to new hire By Investing.com - Investing.com India
Puma Biotechnology, Inc. to Host Earnings Call - ACCESS Newswire
Puma Biotechnology to Present at Barclays 27th Annual Global Healthcare Conference - BioSpace
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference - BioSpace
Puma Biotech grants stock award to new hire - Investing.com
Can Puma Biotechnology's Conference Presentation Signal New Growth Opportunities? - StockTitan
Puma Biotechnology’s Earnings Call: Mixed Sentiments and Future Outlook - MSN
Puma Biotechnology’s (PBYI) Buy Rating Reiterated at HC Wainwright - Defense World
Results: Puma Biotechnology, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates - Nasdaq
Puma Biotechnology: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results - sharewise
Puma Biotechnology Reports Strong Earnings Growth in 2024 - TipRanks
Puma Biotech: Q4 Earnings Snapshot - CTPost
Puma Biotechnology: Hold Rating Amidst Flat Sales Growth and Uncertain Drug Prospects - TipRanks
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Puma Biotech Q4 2024 beats earnings expectations By Investing.com - Investing.com South Africa
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Puma Biotechnology Inc Azioni (PBYI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Puma Biotechnology Inc Azioni (PBYI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ludwig Jeffrey Jerome | Chief Commercial Officer |
Jan 02 '25 |
Sale |
3.15 |
9,437 |
29,743 |
108,951 |
| HUNT DOUGLAS M | See Remarks |
Jan 02 '25 |
Sale |
3.15 |
8,633 |
27,209 |
124,594 |
| AUERBACH ALAN H | President and CEO |
Jan 02 '25 |
Sale |
3.15 |
33,841 |
106,657 |
7,029,674 |
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):